Piper Jaffray analyst Christopher Raymond remains a buyer of Aimmune Therapeutics following the company's presentation of topline results from the Phase 3 Artermis trial yesterday. As expected, the update was in line with data from previous trials, with 58.3% of patients treated with AR101 versus 2.3% of placebo-treated patients tolerating 1,000 mg of peanut protein, Raymond tells investors in a research note. He believes Aimmune's Marketing Authorisation Application for AR101 is on track for mid-year and keeps an Overweight rating on the shares with a $60 price target.